SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Xenomics, Inc., a Florida corporation, on January 13, 2005, covering events occurring on January 10, 2005. The filing discloses the entry into a material definitive agreement and the issuance of unregistered equity securities. Note: The request metadata referenced "Cardiff Oncology, Inc.", but the source text explicitly identifies the registrant as "Xenomics, Inc."
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The financial specifics disclosed relate solely to the new agreement:
- Service Fee: $10,000 per month payable to Trilogy Capital Partners, Inc.
- Equity Issuance: Warrants to purchase 1,000,000 shares of Common Stock.
- Exercise Price: $2.95 per share.
- Warrant Term: Exercisable immediately; expires January 10, 2008.
Material Changes
The primary material change is the engagement of Trilogy Capital Partners, Inc. to provide marketing, financial public relations, and investor relations services for a twelve-month term. Additionally, the company's capital structure was altered by the issuance of 1,000,000 warrants as compensation under this agreement.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general business risks. The transaction was executed in reliance on Section 4(2) of the Securities Act of 1933, meaning it did not involve a public offering. A contingency exists regarding future public offerings: if Xenomics registers common stock for a public offering, it must include the shares underlying these warrants upon Trilogy's request.
Key Facts for Investor Verification
- Verify the total potential dilution from the 1,000,000 warrants issued at a $2.95 exercise price.
- Confirm the company's current cash position to ensure it can sustain the $10,000 monthly fee for the twelve-month term.
- Check subsequent filings to see if the warrants were included in any future registration statements as required by the agreement.
- Clarify the discrepancy between the requested company name (Cardiff Oncology) and the actual registrant (Xenomics, Inc.).